|
|
|
2 | (1) |
| Abbreviations |
|
2 | (1) |
| Journals And Other References |
|
3 | (1) |
|
Table 1 Hepatitis A Virus (HAV) |
|
|
4 | (1) |
|
Table 2 Hepatitis B Virus (HBV) |
|
|
5 | (12) |
|
2A Epidemiology of HBV Infection |
|
|
5 | (1) |
|
2B Natural History of HBV |
|
|
6 | (2) |
|
2C Clinical Presentation of HBV |
|
|
8 | (2) |
|
2D Treatment of HBV (With & Without HIV Coinfection) |
|
|
10 | (3) |
|
2E Hepatitis D (Delta) Virus |
|
|
13 | (1) |
|
2F Hepatitis B Drugs in Development |
|
|
14 | (3) |
|
Table 3 Hepatitis C Virus (HCV) |
|
|
17 | (18) |
|
3A Epidemiology of Hepatitis C (HCV) |
|
|
17 | (1) |
|
|
|
18 | (2) |
|
3C Natural History of HCV Infection |
|
|
20 | (1) |
|
3D Clinical Presentation of HCV |
|
|
21 | (4) |
|
3E HCV Treatment Regimens & Response |
|
|
25 | (6) |
|
3F Hepatitis C Drugs in Development |
|
|
31 | (4) |
|
Table 4 Hepatitis E Virus |
|
|
35 | (1) |
|
Table 5 Anti-HBV, -HCV Drug Dosing & Adverse Effects |
|
|
36 | (6) |
|
Table 6A Pharmacology, Pharmacodynamics of Anti-Hepatitis Drugs |
|
|
42 | (3) |
|
6B Enzyme- & Transporter-Mediated Interactions |
|
|
44 | (1) |
|
Table 7 Dosing Adjustments for Renal Impairment |
|
|
45 | (2) |
|
Table 8 Dosing Adjustments for Hepatic Impairment |
|
|
47 | (1) |
|
Table 9 Management of Exposure to HBV, HCV |
|
|
47 | (3) |
|
Table 10 Hepatitis A & B Immunization |
|
|
50 | (1) |
|
Table 11 Drug-drug Interactions |
|
|
51 | (1) |
|
Table 12 Generic and Trade Names |
|
|
52 | (1) |
| Index Of Major Entities |
|
53 | |
